ResearcherShanghai Jiao Tong UniversityNo recent work listed
Tingting Yan
Matched on ORCID iD 0000-0002-2368-9248; OpenAlex author ID A5061952937. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper
Papers 4
- High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. First author DOI 10.7150/jca.20086↗
- Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
- Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.5939↗
- A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2014.520↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jie Hong · 4 shared papers, 2014–2017 · strength 0.19
- Paper High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with… DOI 10.7150/jca.20086↗
- Paper Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. DOI 10.1038/srep33535↗
- Paper Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcin… DOI 10.18632/oncotarget.5939↗
- Xueliang Fu · 3 shared papers, 2015–2017 · strength 0.15
- Paper High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with… DOI 10.7150/jca.20086↗
- Paper Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. DOI 10.1038/srep33535↗
- Paper Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcin… DOI 10.18632/oncotarget.5939↗
- Yongwei Sun · 3 shared papers, 2015–2017 · strength 0.15
- Paper High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with… DOI 10.7150/jca.20086↗
- Paper Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. DOI 10.1038/srep33535↗
- Paper Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcin… DOI 10.18632/oncotarget.5939↗
- Rong Hua · 3 shared papers, 2015–2017 · strength 0.15
- Paper High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with… DOI 10.7150/jca.20086↗
- Paper Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. DOI 10.1038/srep33535↗
- Paper Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcin… DOI 10.18632/oncotarget.5939↗
- Jian‐Yu Yang · 2 shared papers, 2016–2017 · strength 0.11
- Yan‐Miao Huo · 2 shared papers, 2016–2017 · strength 0.11
- Dejun Liu · 2 shared papers, 2015–2017 · strength 0.10
- Paper High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with… DOI 10.7150/jca.20086↗
- Paper Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcin… DOI 10.18632/oncotarget.5939↗
- Chaoqin Shen · 1 shared paper, 2017 · strength 0.06
- Junfeng Zhang · 1 shared paper, 2017 · strength 0.06
- Wei Chiang Liu · 1 shared paper, 2017 · strength 0.06
- Wei Liu · 1 shared paper, 2016 · strength 0.05
- Minwei Yang · 1 shared paper, 2016 · strength 0.05
- Junfeng Zhang · 1 shared paper, 2016 · strength 0.05
- Linlin Ren · 1 shared paper, 2015 · strength 0.05
- Hui Cao · 1 shared paper, 2014 · strength 0.04
- Rong Hua · 1 shared paper, 2014 · strength 0.04
- Y-W Sun · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.